October 27, 2025
Effective January 1, 2026, we’re updating the HealthSpringSM Medicare Advantage Prescription Drug (MAPD) formularies. Cigna Healthcare® Medicare Advantage is becoming HealthSpring.
To support seamless treatment decisions and care planning, please review the 2026 HealthSpring Medicare Advantage formulary changes in advance. Most members will receive written notification of any changes that may limit access to maintenance medications.
If a formulary alternative is appropriate for your patient, please prescribe it. If no substitute is available, beginning January 1, 2026, submit a prior authorization request. Visit the Medicare Coverage Decisions and Exceptions page for more information.
2026 Formulary Updates
Effective January 1, 2026, these medications will no longer be covered. Please review the 2026 full formulary for a complete list of covered mediations.
| Significant 2026 MAPD formulary removals | ||
| Condition | Formulary removal | 2026 formulary alternative | 
| Diabetes | Bydureon BCISE | Ozempic, Mounjaro, Trulicity | 
| Glyxambi | SGLT-2 (Farxiga or Jardiance) PLUS DPP-4 (Januvia or Tradjenta) | |
| Synjardy/Synjardy XR | Xigduo XR | |
| Tresiba1 | Lantus, Toujeo | |
| Trijardy XR | SGLT-2 (Farxiga or Jardiance) PLUS DPP-4 (Januvia or Tradjenta) PLUS metformin | |
| Diabetes blood glucose monitoring2 | LifeScan OneTouch blood glucose meters and test strips | Abbot’s FreeStyle Lite, Precision Neo, Libre, and Dexcom G6, G7 | 
| Inflammatory conditions | Humira | Hadlima | 
| Inflectra | Remicade | |
| Yuflyma | Hadlima | |
| Migraine | Ajovy | Aimovig | 
| Antipsychotic | Uzedy | Risperidone ER vial | 
| Osteoporosis | Forteo | Teriparatide | 
| Tymlos | Teriparatide | |
1 When switching between basal insulin therapies, the American Diabetes Association (ADA) recommends that “doses can be converted unit for unit and subsequently adjusted based on glucose monitoring; however, an initial dose reduction of 10–20% can be used for individuals in very tight management or at high risk for hypoglycemia.” Please refer to the ADA’s Standards of Care in Diabetes or the prescribing information for additional information.
2 Covered under Part B for Medicare Advantage members, $0 copay for preferred diabetes meters and meter supplies. Coverage: One glucose monitor or one continuous glucose monitor (CGM) every two years; 200 test strips or three sensors per 30-day period (depending on the monitor). Preferred devices: Abbott Diabetes Care – FreeStyle Lite, FreeStyle Freedom Lite, FreeStyle Precision Neo, and FreeStyle Libre (CGM); and Dexcom G6 (CGM) and Dexcom G7 (CGM).
| Significant 2026 MAPD formulary additions | ||
| Condition | Formulary addition | 2026 formulary status | 
| Antipsychotic | Risperidone ER vial | T4/5 QL | 
| Asthma/COPD | Spiriva Respimat | T4 ST/QL | 
| Atopic dermatitis | Zoryve 0.15% cream | T4 PA/QL | 
| Diabetes | Dapagliflozin | T3 QL | 
| Fiasp, insulin aspart, Novolin, Novolog3 | T3 | |
| Inflammatory conditions | Hadlima | T5 PA/QL | 
| Kineret | T5 PA/QL | |
| Selarsdi | T3/5 PA/QL | |
| Stelara | T5 PA/QL | |
| Tyenne | T5 PA/QL | |
| Multiple sclerosis | Teriflunomide | T5 PA/QL | 
| Osteoporosis | Teriparatide | T5 PA/QL | 
| Potassium binder | Lokelma | T3 | 
| Pulmonary hypertension | Winrevair | T5 PA/QL | 
3 $35 insulin per 30-day supply (see formulary for a complete list of covered insulins).
Resources
Cigna Healthcare Medicare Advantage is becoming HealthSpring. Our new benefit plans will be rolled out under the HealthSpring name during the 2025 annual enrollment period. Starting in January 2026, you will begin seeing patients with HealthSpring benefit coverage. Learn more.
Please let us know what you think of the Provider Newsroom information and news.
Contact Us